Radiopharm Theranostics Restricted (ASX: RAD) – Buying and selling Halt

Amgen (NASDAQ:AMGN) as we speak introduced the U.S. Meals and Drug Administration (FDA) has authorised BLINCYTO ® (blinatumomab) for the remedy of grownup and pediatric sufferers one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) within the consolidation section, no matter measurable residual illness (MRD) standing.

“B-ALL is an aggressive blood most cancers with enduring excessive unmet want. BLINCYTO has helped 1000’s of sufferers with B-ALL during the last 10 years. As we speak’s approval within the frontline consolidation section, no matter MRD standing, permits us to achieve extra sufferers than ever with this transformative, first-in-class Bispecific T-cell Engager (BiTE ^® ) remedy,” stated Jay Bradner , M.D., government vice chairman, Analysis and Improvement, and chief scientific officer at Amgen.

The approval marks the third indication for BLINCYTO and relies totally on the Section 3 E1910 scientific trial led by ECOG-ACRIN Most cancers Analysis Group that studied sufferers with newly recognized Philadelphia chromosome-negative B-ALL receiving postinduction consolidation remedy, which goals to deepen remission to realize sturdy responses. Examine outcomes demonstrated that BLINCYTO added to multiphase consolidation chemotherapy confirmed superior total survival (OS) versus chemotherapy alone. The three-year OS was 84.8% within the BLINCYTO plus chemotherapy arm (n=112) and 69% within the chemotherapy arm (n=112), with the hazard ratio for OS of 0.42. With a median follow-up of 4.5 years, the 5-year OS was 82.4% within the BLINCYTO plus chemotherapy arm and 62.5% within the chemotherapy arm.

“Within the E1910 research, blinatumomab decreased threat of dying and confirmed a outstanding enchancment in total survival,” stated Selina M. Luger , M.D., professor of hematology-oncology on the College of Pennsylvania’s Perelman Faculty of Medication and Abramson Most cancers Heart, chair of the ECOG-ACRIN Leukemia Committee and an investigator on the research. “This approval redefines the usual of take care of sufferers with B-ALL and supplies them with a simpler remedy possibility than normal chemotherapy alone.”

“The danger of B-ALL recurrence after the preliminary section of remedy is comparatively excessive, making this approval for sufferers noteworthy,” stated E. Anders Kolb , M.D., president and chief government officer of The Leukemia & Lymphoma Society. “B-ALL is the most typical sort of ALL and having one other efficient possibility accessible earlier in a affected person’s remedy journey is important for clinicians who’re working to offer these sufferers extra time with their family members.”

The E1910 research was designed and carried out independently from trade. ECOG-ACRIN sponsored the trial with public funding from the Nationwide Most cancers Institute (NCI), a part of the Nationwide Institutes of Well being (NIH). Different NCI-funded community teams took half within the research. As well as, Amgen supplied BLINCYTO and help via an NCI Cooperative Analysis and Improvement Settlement.

About Acute Lymphoblastic Leukemia (ALL)
ALL, also referred to as acute lymphoblastic leukemia, is a fast-growing sort of blood most cancers that develops within the bone marrow and might typically unfold to different elements of the physique, together with the lymph nodes, liver, spleen, and central nervous system. ALL is a uncommon illness, with 6,540 new circumstances recognized within the U.S. in 2023 affecting each youngsters and adults. ¹ B-ALL begins in immature cells that might usually become B-cell lymphocytes, that are white blood cells that develop in bone marrow. ^2,3 B-ALL is the most typical sort of ALL, constituting roughly 75% of circumstances in adults. ⁴

About BLINCYTO ^® (blinatumomab)
BLINCYTO is the primary globally authorised BiTE ^® immuno-oncology remedy that targets CD19 floor antigens on B cells. BiTE ^® molecules battle most cancers by serving to the physique’s immune system detect and goal malignant cells by participating T cells (a sort of white blood cell able to killing different cells perceived as threats) to most cancers cells. By bringing T cells close to most cancers cells, the T cells can inject toxins and set off most cancers cell dying (apoptosis). BiTE ^® immuno-oncology therapies are presently being investigated for his or her potential to deal with all kinds of cancers.

BLINCYTO was granted breakthrough remedy and Precedence Overview designations by the U.S. FDA and is authorised within the U.S. for the remedy of:

• Grownup and pediatric sufferers one month or older with CD19-positive Philadelphia chromosome-negative B-ALL in the course of the consolidation section of multiphase remedy.
• CD19-positive B-ALL in first or second full remission with MRD better than or equal to 0.1% in adults and pediatric sufferers one month or older.
• Relapsed or refractory CD19-positive B-ALL in adults and pediatric sufferers one month or older.

Within the European Union (EU), BLINCYTO is indicated as monotherapy for the remedy of:

• Adults with Philadelphia chromosome-negative CD19-positive relapsed or refractory B-ALL. Sufferers with Philadelphia chromosome-positive B-ALL ought to have failed remedy with no less than two tyrosine kinase inhibitors (TKIs) and don’t have any different remedy choices.
• Adults with Philadelphia chromosome-negative CD19-positive B-ALL in first or second full remission with MRD better than or equal to 0.1%.
• Pediatric sufferers aged 1 12 months or older with Philadelphia chromosome-negative CD19-positive B-ALL which is refractory or in relapse after receiving no less than two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.
• Pediatric sufferers aged 1 12 months or older with high-risk first relapsed Philadelphia chromosome-negative CD19-positive B-ALL as a part of the consolidation remedy.

INDICATIONS

BLINCYTO ^® (blinatumomab) is indicated for the remedy of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in grownup and pediatric sufferers one month and older with:

• Philadelphia chromosome-negative illness within the consolidation section of multiphase chemotherapy.
• Minimal residual illness (MRD) better than or equal to 0.1% in first or second full remission.
• Relapsed or refractory illness.

BLINCYTO ^® IMPORTANT SAFETY INFORMATION

WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES together with IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME

• Cytokine Launch Syndrome (CRS), which can be life-threatening or deadly, occurred in sufferers receiving BLINCYTO ^® . Interrupt or discontinue BLINCYTO ^® and deal with with corticosteroids as really helpful.
• Neurological toxicities, together with immune effector cell-associated neurotoxicity syndrome (ICANS) which can be extreme, life-threatening, or deadly, occurred in sufferers receiving BLINCYTO ^® . Interrupt or discontinue BLINCYTO ^® as really helpful.

Contraindications

BLINCYTO ^® is contraindicated in sufferers with a recognized hypersensitivity to blinatumomab or to any element of the product formulation.

Warnings and Precautions

• Cytokine Launch Syndrome (CRS): CRS, which can be life-threatening or deadly, occurred in sufferers receiving BLINCYTO ^® . The median time to onset of CRS is 2 days after the beginning of infusion and the median time to decision of CRS was 5 days amongst circumstances that resolved. Carefully monitor and advise sufferers to contact their healthcare skilled for indicators and signs of significant hostile occasions resembling fever, headache, nausea, asthenia, hypotension, elevated alanine aminotransferase (ALT), elevated aspartate aminotransferase (AST), elevated complete bilirubin (TBILI), and disseminated intravascular coagulation (DIC). The manifestations of CRS after remedy with BLINCYTO ^® overlap with these of infusion reactions, capillary leak syndrome (CLS), and hemophagocytic histiocytosis/macrophage activation syndrome (MAS). Utilizing all of those phrases to outline CRS in scientific trials of BLINCYTO ^® , CRS was reported in 15% of sufferers with R/R ALL, in 7% of sufferers with MRD-positive ALL, and in 16% of sufferers receiving BLINCYTO ^® cycles within the consolidation section of remedy. If extreme CRS happens, interrupt BLINCYTO ^® till CRS resolves. Discontinue BLINCYTO ^® completely if life-threatening CRS happens. Administer corticosteroids for extreme or life-threatening CRS.
• Neurological Toxicities , together with Immune Effector Cell-Related Neurotoxicity Syndrome: BLINCYTO ^® could cause critical or life-threatening neurologic toxicity, together with ICANS. The incidence of neurologic toxicities in scientific trials was roughly 65%. The median time to the primary occasion was inside the first 2 weeks of BLINCYTO ^® remedy. The most typical (≥ 10%) manifestations of neurological toxicity have been headache and tremor. Grade 3 or greater neurological toxicities occurred in roughly 13% of sufferers, together with encephalopathy, convulsions, speech problems, disturbances in consciousness, confusion and disorientation, and coordination and steadiness problems. Manifestations of neurological toxicity included cranial nerve problems. The vast majority of neurologic toxicities resolved following interruption of BLINCYTO ^® , however some resulted in remedy discontinuation.

  The incidence of indicators and signs in keeping with ICANS in scientific trials was 7.5%. The onset of ICANS may be concurrent with CRS, following decision of CRS, or within the absence of CRS. There’s restricted expertise with BLINCYTO ^® in sufferers with lively ALL within the central nervous system (CNS) or a historical past of neurologic occasions. Sufferers with a historical past or presence of clinically related CNS pathology have been excluded from scientific research. Sufferers with Down Syndrome over the age of 10 years could have the next threat of seizures with BLINCYTO ^® remedy.

  Monitor sufferers for indicators and signs of neurological toxicities, together with ICANS, and interrupt or discontinue BLINCYTO ^® as outlined within the PI. Advise outpatients to contact their healthcare skilled in the event that they develop indicators or signs of neurological toxicities.

• Infections: Roughly 25% of sufferers receiving BLINCYTO ^® in scientific trials skilled critical infections resembling sepsis, pneumonia, bacteremia, opportunistic infections, and catheter-site infections, a few of which have been life-threatening or deadly. Administer prophylactic antibiotics and make use of surveillance testing as applicable throughout remedy. Monitor sufferers for indicators or signs of an infection and deal with appropriately, together with interruption or discontinuation of BLINCYTO ^® as wanted.
• Tumor Lysis Syndrome (TLS), which can be life-threatening or deadly, has been noticed. Preventive measures, together with pretreatment unhazardous cytoreduction and on-treatment hydration, must be used throughout BLINCYTO ^® remedy. Monitor sufferers for indicators and signs of TLS and interrupt or discontinue BLINCYTO ^® as wanted to handle these occasions.
• Neutropenia and Febrile Neutropenia, together with life-threatening circumstances, have been noticed. Monitor applicable laboratory parameters (together with, however not restricted to, white blood cell rely and absolute neutrophil rely) throughout BLINCYTO ^® infusion and interrupt BLINCYTO ^® if extended neutropenia happens.
• Results on Capability to Drive and Use Machines: Because of the opportunity of neurological occasions, together with seizures and ICANS, sufferers receiving BLINCYTO ^® are in danger for lack of consciousness, and must be suggested towards driving and fascinating in hazardous occupations or actions resembling working heavy or probably harmful equipment whereas BLINCYTO ^® is being administered.
• Elevated Liver Enzymes: Transient elevations in liver enzymes have been related to BLINCYTO ^® remedy with a median time to onset of three days. In sufferers receiving BLINCYTO ^® , though the vast majority of these occasions have been noticed within the setting of CRS, some circumstances of elevated liver enzymes have been noticed outdoors the setting of CRS, with a median time to onset of 19 days. Grade 3 or better elevations in liver enzymes occurred in roughly 7% of sufferers outdoors the setting of CRS and resulted in remedy discontinuation in lower than 1% of sufferers. Monitor ALT, AST, gamma-glutamyl transferase, and complete blood bilirubin previous to the beginning of and through BLINCYTO ^® remedy. BLINCYTO ^® remedy must be interrupted if transaminases rise to > 5 instances the higher restrict of regular (ULN) or if complete bilirubin rises to > 3 instances ULN.
• Pancreatitis: Deadly pancreatitis has been reported in sufferers receiving BLINCYTO ^® together with dexamethasone in scientific trials and the post-marketing setting. Consider sufferers who develop indicators and signs of pancreatitis and interrupt or discontinue BLINCYTO ^® and dexamethasone as wanted.
• Leukoencephalopathy: Though the scientific significance is unknown, cranial magnetic resonance imaging (MRI) modifications displaying leukoencephalopathy have been noticed in sufferers receiving BLINCYTO ^® , particularly in sufferers beforehand handled with cranial irradiation and antileukemic chemotherapy.
• Preparation and administration errors have occurred with BLINCYTO ^® remedy. Comply with directions for preparation (together with admixing) and administration within the PI strictly to attenuate medicine errors (together with underdose and overdose).
• Immunization: Vaccination with stay virus vaccines isn’t really helpful for no less than 2 weeks previous to the beginning of BLINCYTO ^® remedy, throughout remedy, and till immune restoration following final cycle of BLINCYTO ^® .
• Benzyl Alcohol Toxicity in Neonates: Critical hostile reactions, together with deadly reactions and the “gasping syndrome,” have been reported in very low delivery weight (VLBW) neonates born weighing lower than 1500 g, and early preterm neonates (infants born lower than 34 weeks gestational age) who obtained intravenous medication containing benzyl alcohol as a preservative. Early preterm VLBW neonates could also be extra prone to develop these reactions, as a result of they could be much less capable of metabolize benzyl alcohol.

  Use the preservative-free preparations of BLINCYTO ^® the place potential in neonates. When prescribing BLINCYTO ^® (with preservative) for neonatal sufferers, think about the mixed every day metabolic load of benzyl alcohol from all sources together with BLINCYTO ^® (with preservative), different merchandise containing benzyl alcohol or different excipients (e.g., ethanol, propylene glycol) which compete with benzyl alcohol for a similar metabolic pathway.

  Monitor neonatal sufferers receiving BLINCYTO ^® (with preservative) for brand new or worsening metabolic acidosis. The minimal quantity of benzyl alcohol at which critical hostile reactions could happen in neonates isn’t recognized. The BLINCYTO ^® 7-Day bag (with preservative) incorporates 7.4 mg of benzyl alcohol per mL.

• Embryo-Fetal Toxicity: Primarily based on its mechanism of motion, BLINCYTO ^® could trigger fetal hurt when administered to a pregnant girl. Advise pregnant ladies of the potential threat to the fetus. Advise females of reproductive potential to make use of efficient contraception throughout remedy with BLINCYTO ^® and for 48 hours after the final dose.

Antagonistic Reactions

• The protection of BLINCYTO ^® in grownup and pediatric sufferers one month and older with MRD-positive B-cell precursor ALL (n=137), relapsed or refractory B-cell precursor ALL (n=267), and Philadelphia chromosome-negative B cell precursor ALL in consolidation (n=165) was evaluated in scientific research. The most typical hostile reactions (≥ 20%) to BLINCYTO ^® on this pooled inhabitants have been pyrexia, infusion-related reactions, headache, an infection, musculoskeletal ache, neutropenia, nausea, anemia, thrombocytopenia, and diarrhea.

Dosage and Administration Pointers

• BLINCYTO ^® is run as a steady intravenous infusion at a continuing move charge utilizing an infusion pump which must be programmable, lockable, non-elastomeric, and have an alarm.
• It is rather necessary that the directions for preparation (together with admixing) and administration supplied within the full Prescribing Data are strictly adopted to attenuate medicine errors (together with underdose and overdose).

Please see BLINCYTO ^® full Prescribing Data , together with BOXED WARNINGS.

About BiTE ^® Know-how
Bispecific T-cell Engager (BiTE ^® ) know-how is a focused immuno-oncology platform that’s designed to interact affected person’s personal T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to get rid of detectable most cancers. The BiTE ^® immuno-oncology platform has the potential to deal with completely different tumor sorts via tumor-specific antigens. The BiTE ^® platform has a objective of resulting in off-the-shelf options, which have the potential to make progressive T cell remedy accessible to all suppliers when their sufferers want it. Amgen is advancing a number of BiTE ^® molecules throughout a broad vary of hematologic malignancies and stable tumors, additional investigating BiTE ^® know-how with the objective of enhancing affected person expertise and therapeutic potential. To be taught extra about BiTE ^® know-how, go to https://www.amgenoncology.com/bite-platform.html .

About Amgen
Amgen discovers, develops, manufactures and delivers progressive medicines to assist hundreds of thousands of sufferers of their battle towards among the world’s hardest ailments. Greater than 40 years in the past, Amgen helped to ascertain the biotechnology trade and stays on the cutting-edge of innovation, utilizing know-how and human genetic knowledge to push past what’s recognized as we speak. Amgen is advancing a broad and deep pipeline that builds on its present portfolio of medicines to deal with most cancers, coronary heart illness, osteoporosis, inflammatory ailments and uncommon ailments.

In 2024, Amgen was named one of many “World’s Most Revolutionary Firms” by Quick Firm and one in every of “America’s Greatest Massive Employers” by Forbes, amongst different exterior recognitions . Amgen is likely one of the 30 firms that comprise the Dow Jones Industrial Common ^® , and it is usually a part of the Nasdaq-100 Index ^® , which incorporates the biggest and most progressive non-financial firms listed on the Nasdaq Inventory Market primarily based on market capitalization.

For extra info, go to Amgen.com and observe Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads .

Amgen Ahead-Wanting Statements
This information launch incorporates forward-looking statements which are primarily based on the present expectations and beliefs of Amgen. All statements, apart from statements of historic reality, are statements that could possibly be deemed forward-looking statements, together with any statements on the result, advantages and synergies of collaborations, or potential collaborations, with every other firm (together with BeiGene, Ltd. or Kyowa-Kirin Co., Ltd.), the efficiency of Otezla ^® (apremilast) (together with anticipated Otezla gross sales development and the timing of non-GAAP EPS accretion), the Teneobio, Inc. acquisition, the ChemoCentryx, Inc. acquisition, or the Horizon Therapeutics plc acquisition (together with the potential efficiency and outlook of Horizon’s enterprise, efficiency and alternatives, any potential strategic advantages, synergies or alternatives anticipated because of such acquisition), and any projected impacts from the Horizon acquisition on our acquisition associated bills going ahead, in addition to estimates of revenues, working margins, capital expenditures, money, different monetary metrics, anticipated authorized, arbitration, political, regulatory or scientific outcomes or practices, buyer and prescriber patterns or practices, reimbursement actions and outcomes, results of pandemics or different widespread well being issues on our enterprise, outcomes, progress, and different such estimates and outcomes. Ahead-looking statements contain important dangers and uncertainties, together with these mentioned beneath and extra totally described within the Securities and Change Fee studies filed by Amgen, together with our most up-to-date annual report on Kind 10-Ok and any subsequent periodic studies on Kind 10-Q and present studies on Kind 8-Ok. Except in any other case famous, Amgen is offering this info as of the date of this information launch and doesn’t undertake any obligation to replace any forward-looking statements contained on this doc because of new info, future occasions or in any other case.

No forward-looking assertion may be assured and precise outcomes could differ materially from these we mission. Discovery or identification of recent product candidates or growth of recent indications for present merchandise can’t be assured and motion from idea to product is unsure; consequently, there may be no assure that any explicit product candidate or growth of a brand new indication for an present product shall be profitable and turn out to be a industrial product. Additional, preclinical outcomes don’t assure protected and efficient efficiency of product candidates in people. The complexity of the human physique can’t be completely, or typically, even adequately modeled by laptop or cell tradition programs or animal fashions. The size of time that it takes for us to finish scientific trials and acquire regulatory approval for product advertising and marketing has up to now different and we anticipate related variability sooner or later. Even when scientific trials are profitable, regulatory authorities could query the sufficiency for approval of the trial endpoints we have now chosen. We develop product candidates internally and thru licensing collaborations, partnerships and joint ventures. Product candidates which are derived from relationships could also be topic to disputes between the events or could show to be not as efficient or as protected as we could have believed on the time of coming into into such relationship. Additionally, we or others may establish security, uncomfortable side effects or manufacturing issues with our merchandise, together with our gadgets, after they’re available on the market.

Our outcomes could also be affected by our potential to efficiently market each new and present merchandise domestically and internationally, scientific and regulatory developments involving present and future merchandise, gross sales development of lately launched merchandise, competitors from different merchandise together with biosimilars, difficulties or delays in manufacturing our merchandise and international financial circumstances. As well as, gross sales of our merchandise are affected by pricing strain, political and public scrutiny and reimbursement insurance policies imposed by third-party payers, together with governments, non-public insurance coverage and managed care suppliers and could also be affected by regulatory, scientific and guideline developments and home and worldwide developments towards managed care and healthcare value containment. Moreover, our analysis, testing, pricing, advertising and marketing and different operations are topic to intensive regulation by home and international authorities regulatory authorities. Our enterprise could also be impacted by authorities investigations, litigation and product legal responsibility claims. As well as, our enterprise could also be impacted by the adoption of recent tax laws or publicity to further tax liabilities. If we fail to fulfill the compliance obligations within the company integrity settlement between us and the U.S. authorities, we may turn out to be topic to important sanctions. Additional, whereas we routinely receive patents for our merchandise and know-how, the safety provided by our patents and patent functions could also be challenged, invalidated or circumvented by our opponents, or we could fail to prevail in current and future mental property litigation. We carry out a considerable quantity of our industrial manufacturing actions at just a few key amenities, together with in Puerto Rico , and likewise rely upon third events for a portion of our manufacturing actions, and limits on provide could constrain gross sales of sure of our present merchandise and product candidate growth. An outbreak of illness or related public well being risk, resembling COVID-19, and the general public and governmental effort to mitigate towards the unfold of such illness, may have a big hostile impact on the provision of supplies for our manufacturing actions, the distribution of our merchandise, the commercialization of our product candidates, and our scientific trial operations, and any such occasions could have a cloth hostile impact on our product growth, product gross sales, enterprise and outcomes of operations. We depend on collaborations with third events for the event of a few of our product candidates and for the commercialization and gross sales of a few of our industrial merchandise. As well as, we compete with different firms with respect to lots of our marketed merchandise in addition to for the invention and growth of recent merchandise. Additional, some uncooked supplies, medical gadgets and element elements for our merchandise are provided by sole third-party suppliers. Sure of our distributors, prospects and payers have substantial buying leverage of their dealings with us. The invention of great issues with a product just like one in every of our merchandise that implicate a whole class of merchandise may have a cloth hostile impact on gross sales of the affected merchandise and on our enterprise and outcomes of operations. Our efforts to collaborate with or purchase different firms, merchandise or know-how, and to combine the operations of firms or to help the merchandise or know-how we have now acquired, is probably not profitable. There may be no assure that we can notice any of the strategic advantages, synergies or alternatives arising from the Horizon acquisition, and such advantages, synergies or alternatives could take longer to understand than anticipated. We could not be capable to efficiently combine Horizon, and such integration could take longer, be tougher or value greater than anticipated. A breakdown, cyberattack or info safety breach of our info know-how programs may compromise the confidentiality, integrity and availability of our programs and our knowledge. Our inventory worth is risky and could also be affected by plenty of occasions. Our enterprise and operations could also be negatively affected by the failure, or perceived failure, of attaining our environmental, social and governance aims. The results of world local weather change and associated pure disasters may negatively have an effect on our enterprise and operations. World financial circumstances could amplify sure dangers that have an effect on our enterprise. Our enterprise efficiency may have an effect on or restrict the flexibility of our Board of Administrators to declare a dividend or our potential to pay a dividend or repurchase our frequent inventory. We could not be capable to entry the capital and credit score markets on phrases which are favorable to us, or in any respect.

CONTACT: Amgen, Thousand Oaks
Elissa Snook , 609-251-1407 (media)
Justin Claeys , 805-313-9775 (traders)

Editor’s word: Dr. Luger has obtained honoraria for an Amgen-sponsored instructional symposium.

1. Nationwide Most cancers Institute. Accessible at: https://seer.most cancers.gov/statfacts/html/alyl.html . Accessed on February 8, 2024 .
2. Terwilliger T, et al. Blood Most cancers J . doi:10.1038/bcj.2017.53.
3. Most cancers.org. Accessible at: https://www.most cancers.org/most cancers/sorts/acute-lymphocytic-leukemia/about/what-is-all.html Accessed on February 8, 2024 .
4. Leukemia & Lymphoma Society. Accessible at: https://www.lls.org/analysis/acute-lymphoblastic-leukemia-all#:~:textual content=Bpercent2DALLpercent20ispercent20morepercent20common,aboutpercent2075percent20percentpercent20ofpercent20cases . Accessed on February 8, 2024 .

View unique content material to obtain multimedia: https://www.prnewswire.com/news-releases/fda-approves-blincyto-blinatumomab-in-cd19-positive-philadelphia-chromosome-negative-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-in-the-consolidation-phase-302173376.html

SOURCE Amgen